Patents Assigned to ModernaTX, Inc.
  • Publication number: 20250051736
    Abstract: Described here are genetically modified microorganisms with reduced protease activity for the expression of recombinant proteins and without mucoid phenotypes. Also described are methods of making and using the same.
    Type: Application
    Filed: October 17, 2022
    Publication date: February 13, 2025
    Applicant: ModernaTX, Inc.
    Inventor: Kevin Smith
  • Publication number: 20250041407
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having a open reading frame encoding at least varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: January 18, 2024
    Publication date: February 6, 2025
    Applicant: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • Patent number: 12208288
    Abstract: The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
    Type: Grant
    Filed: July 2, 2024
    Date of Patent: January 28, 2025
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 12195778
    Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
    Type: Grant
    Filed: August 11, 2023
    Date of Patent: January 14, 2025
    Assignee: ModernaTX, Inc.
    Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
  • Publication number: 20250011798
    Abstract: Provided herein are genetically modified microorganisms comprising a nonsense mutation in a gene encoding an efflux pump or import protein, and a vector encoding a suppressor tRNA that enables translation of the efflux pump or import protein, mitigating the effect of the nonsense mutation. Also provided are methods of producing a vector or markerless DNA using the genetically modified microorganisms provided herein.
    Type: Application
    Filed: October 17, 2022
    Publication date: January 9, 2025
    Applicant: ModernaTX, Inc.
    Inventors: Kevin Smith, Joe R. Sarkis, Stoil Dimitrov
  • Patent number: 12180518
    Abstract: The present disclosure provides RNA polymerase variants for high efficiency transcription.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: December 31, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith, Michelle Lynn Hall
  • Publication number: 20240408191
    Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
    Type: Application
    Filed: August 12, 2024
    Publication date: December 12, 2024
    Applicant: ModernaTX, INC.
    Inventors: Giuseppe CIARAMELLA, Axel BOUCHON, Eric YI-CHUN HUANG
  • Publication number: 20240398931
    Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
    Type: Application
    Filed: August 12, 2024
    Publication date: December 5, 2024
    Applicant: ModernaTX, INC.
    Inventors: Giuseppe CIARAMELLA, Axel BOUCHON, Eric YI-CHUN HUANG
  • Publication number: 20240398927
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
    Type: Application
    Filed: February 28, 2022
    Publication date: December 5, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
  • Publication number: 20240390480
    Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
    Type: Application
    Filed: August 12, 2024
    Publication date: November 28, 2024
    Applicant: ModernaTX, INC.
    Inventors: Giuseppe CIARAMELLA, Axel BOUCHON, Eric YI-CHUN HUANG
  • Patent number: 12151995
    Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
    Type: Grant
    Filed: September 14, 2023
    Date of Patent: November 26, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Kerry E. Benenato, Mark Cornebise, Ellalahewage Sathyajith Kumarasinghe
  • Patent number: 12150980
    Abstract: The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: November 26, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Nicholas Valiante, Tal Zaks
  • Patent number: 12151029
    Abstract: The present disclosure in part provides compounds (i.e., PEG lipids) which are useful in pharmaceutical compositions, cosmetic compositions, and drug delivery systems, e.g, for use in lipid nanoparticle (LNP) formulations. The present disclosure also provides LNP formulations comprising PEG lipids described herein, and methods of using the same. For example, the LNPs provided herein are useful for the delivery of an agent (e.g, therapeutic agent) to a subject. The PEG lipids and LNPs provided herein, in certain embodiments, exhibit increased PEG shedding compared to existing PEG lipids and LNP formulations.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: November 26, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Edward J. Hennessy, Kerry Benenato
  • Publication number: 20240382581
    Abstract: The disclosure relates to pan human coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: July 8, 2022
    Publication date: November 21, 2024
    Applicant: ModernaTX, Inc.
    Inventor: Guillaume Stewart-Jones
  • Patent number: 12144895
    Abstract: The disclosure features a lipid nanoparticle (LNP) formulation comprising a plurality of LNPs and a stabilizing agent that mitigates the degradation of the LNPs or a subpopulation thereof. Lipid nanoparticles further including therapeutics and/or prophylactics such as RNA are useful in the delivery of therapeutics and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression. Methods of manufacturing LNP formulations and screening for a stabilizing agent are also disclosed.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: November 19, 2024
    Assignee: ModernaTX, Inc.
    Inventor: Mark Brader
  • Publication number: 20240366749
    Abstract: The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: July 2, 2024
    Publication date: November 7, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe CIARAMELLA, Sunny HIMANSU
  • Publication number: 20240366748
    Abstract: The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: July 2, 2024
    Publication date: November 7, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe CIARAMELLA, Sunny HIMANSU
  • Publication number: 20240366745
    Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
    Type: Application
    Filed: April 15, 2024
    Publication date: November 7, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
  • Publication number: 20240368580
    Abstract: Described herein are methods of purifying nucleic acids (e.g., mRNAs) from feed solutions using continuous, multicolumn chromatography approaches. Also described are methods of increasing the efficiency of chromatography methods by performing purification methods in parallel using multiple columns.
    Type: Application
    Filed: August 12, 2022
    Publication date: November 7, 2024
    Applicant: ModernaTX, inc.
    Inventors: Mark Geng, Jason Murphy, Lei ZHOU, James Sinoimeri, Tahir Kapoor, Joseph Elich
  • Publication number: 20240358819
    Abstract: The disclosure relates to pan human coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: July 8, 2022
    Publication date: October 31, 2024
    Applicant: ModernaTX, Inc.
    Inventor: Guillaume Stewart-Jones